Loading...
01/10 01:21
Loading...
Neogenomics Inc (NEO) is set to release its earnings performance on 04/29 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 170.90M and an earnings per share (EPS) of -0.11 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings call summary presents a mixed picture. While there are positive elements such as NGS growth and new product launches like PanTracer, there are also challenges like revised revenue guidance due to pharma uncertainties and potential negative EBITDA impact from Pathline integration. The Q&A session highlighted management's optimism but also revealed some vagueness in responses, particularly around timelines and competitive positioning. Given the company's small-cap status, the stock is likely to remain stable, leading to a neutral prediction.
The earnings call summary shows mixed signals. While the company has a strong product development and partnership strategy, financial performance is affected by delays and market challenges. The Q&A reveals management's confidence in guidance despite uncertainties, but also highlights risks such as litigation and limited visibility in pharma services. The positive aspects such as the Pathline acquisition and NGS growth are balanced by cautious guidance and challenges in the pharma market. Given the company's market cap, the stock price is likely to remain stable in the short term, leading to a neutral prediction.
The earnings call summary presents a mixed picture. Financial performance shows revenue growth, but EPS missed expectations. Product development is promising with new launches and NGS growth. Market strategy is strong, but operational challenges exist. Expenses are a concern with negative cash flow, though margins improved. No share repurchase plan is a negative. Q&A insights suggest optimism but also highlight non-clinical revenue declines and cautious guidance. Given the company's small-cap status, these factors balance out to a neutral sentiment, expecting minor stock price fluctuations in the short term.
The earnings call reveals strong financial performance with significant growth in adjusted EBITDA and clinical revenue, despite a decline in non-clinical revenue. The Q&A indicates optimism about product contributions and strategic focus. Although there are some concerns about non-clinical business decline, the overall sentiment is positive due to strong NGS growth, improved margins, and strategic investments. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8%.
Neogenomics Inc (NEO) is scheduled to release its FY2025Q1 earnings report onApr 29, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 170.90M in revenue and an EPS of -0.11 for Neogenomics Inc's FY2025Q1.
Intellectia's exclusive AI algorithms forecast a forNeogenomics Inc's FY2025Q1 earnings, with a prediction date of Apr 29, 2025. Neogenomics Inc
Leverage Intellectia's AI forecast to position trades ahead of theApr 29, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
